Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.72 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.58 |
| ▸ | MGAM | O43451 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634365 | 0.85 | MEN1 (0.62) | KMOAMY1ASTAT3PKMALDH1A1 | |
| SCHEMBL633394 | 0.84 | KMO (0.70) | KMOAMY1AMGAMGAASI | |
| SCHEMBL633155 | 0.83 | KMO (0.71) | KMOSTAT3POLBPKMPLAU | |
| SCHEMBL429355 | 0.82 | KMO (1.00) | KMOSTAT3POLBPLAUALDH1A1 | |
| SCHEMBL10148194 | 0.82 | KMO (0.84) | KMOSTAT3POLBPLAUALDH1A1 | |
| SCHEMBL424256 | 0.82 | KMO (1.00) | KMOPOLBMEN1KMT2A | |
| SCHEMBL633335 | 0.82 | KMO (0.65) | KMOSTAT3POLBPLAUMEN1 | |
| SCHEMBL29379527 | 0.82 | KMO (1.00) | KMOPOLBMEN1KMT2A | |
| SCHEMBL17146455 | 0.81 | KMO (0.82) | KMOSTAT3POLBPLAUALDH1A1 | |
| SCHEMBL424487 | 0.81 | KMO (0.81) | KMOSTAT3POLBPLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420494-B1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2014-10-08 | — | — | EP | claimed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | claimed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | claimed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | claimed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | claimed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | claimed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2016193499-A1 | IMMUNOMODULATORY ANTIBODY OR IMMUNOTHERAPEUTIC, AGENT WHICH INCREASES AND/OR MIMICKS KYNURENINE, AND OPTIONAL COMBINATION THEREOF | IMMUSMOL SAS (FR) | 2016-12-08 | — | — | WO | disclosed |
| EP-2420494-B1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | KMO 1/4885AMY1A 4241/4885MGAM 2026/4885 |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | KMO 1/4885AMY1A 4241/4885MGAM 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.